Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;59(8):4930-7.
doi: 10.1128/AAC.00970-15. Epub 2015 Jun 8.

Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides

Affiliations

Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides

Arnold S Bayer et al. Antimicrob Agents Chemother. 2015 Aug.

Abstract

MprF is responsible for the lysinylation of phosphatidylglycerol (PG) to synthesize the positively charged phospholipid (PL) species, lysyl-PG (L-PG). It has been proposed that the single-nucleotide polymorphisms (SNPs) within the mprF open reading frame (ORF) are associated with a gain-in-function phenotype in terms of daptomycin resistance in Staphylococcus aureus. (Note that although the official term is daptomycin nonsusceptibility, we use the term daptomycin resistance in this paper for ease of presentation.) Using 22 daptomycin-susceptible (DAP(s))/daptomycin-resistant (DAP(r)) clinical methicillin-resistant S. aureus (MRSA) strain pairs, we assessed (i) the frequencies and distribution of putative mprF gain-in-function SNPs, (ii) the relationships of the SNPs to both daptomycin resistance and cross-resistance to the prototypical endovascular host defense peptide (HDP) thrombin-induced platelet microbicidal protein (tPMP), and (iii) the impact of mprF SNPs on positive surface charge phenotype and modifications of membrane PL profiles. Most of the mprF SNPs identified in our DAP(r) strains were clustered within the two MprF loci, (i) the central bifunctional domain and (ii) the C-terminal synthase domain. Moreover, we were able to correlate the presence and location of mprF SNPs in DAP(r) strains with HDP cross-resistance, positive surface charge, and L-PG profiles. Although DAP(r) strains with mprF SNPs in the bifunctional domain showed higher resistance to tPMPs than DAP(r) strains with SNPs in the synthase domain, this relationship was not observed in positive surface charge assays. These results demonstrated that both charge-mediated and -unrelated mechanisms are involved in DAP resistance and HDP cross-resistance in S. aureus.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Location of the point mutations within the MprF protein. The multiple peptide resistance factor (MprF) of S. aureus is a bifunctional enzyme that synthesizes positively charged L-PG and facilitates L-PG translocation from the inner to the outer leaflet of the CM. MprF consists of a C-terminal L-PG synthase domain, an N-terminal L-PG translocase (flippase) domain, and a central bifunctional domain bridging the synthase and translocase domains. The predicted MprF topology was modified from previous publications (13, 19).
FIG 2
FIG 2
Binding of positively charged cytochrome c to whole S. aureus cells. The graph shows percentage of cytochrome c bound after 15 min of incubation with S. aureus cells at room temperature. The less cytochrome c bound, the more positively charged the bacterial surface. The data represent the means (± SD) from three independent experiments. Each DAPs parental S. aureus strain was normalized to 100% (e.g., bar graph of DAPr strain C2 is compared to its DAPs parental strain, set at 100%). *, P < 0.01 versus respective DAPs parental strains.

References

    1. Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS, ICE Investigators. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012–3021. doi:10.1001/jama.293.24.3012. - DOI - PubMed
    1. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG Jr, International Collaboration on Endocarditis Merged Database Study Group. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41:507–514. doi:10.1086/431979. - DOI - PubMed
    1. Ammerlaan HSM, Harbarth S, Buiting AGM, Crook DW, Fitzpatrick F, Hanberger H, Herwaldt LA, van Keulen PHJ, Kluytmans JAJW, Kola A, Kuchenbecker RS, Lingaas E, Meessen N, Morris-Downes MM, Pottinger JM, Rohner P, dos Santos RP, Seifert H, Wisplinghoff H, Ziesing S, Walker AS, Bonten MJM. 2013. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 56:798–805. doi:10.1093/cid/cis1006. - DOI - PubMed
    1. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60:334–340. doi:10.1093/jac/dkm170. - DOI - PubMed
    1. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62:1145–1158. - PubMed

Publication types

MeSH terms